Se ti disconnetti da Login UE, uscirai anche da tutti gli altri servizi che usano il tuo account Login UE. Utilizza il pulsante di disconnessione di CORDIS per rimanere connesso agli altri servizi.
Questa pagina sarà tradotta automaticamente dal servizio eTranslation della Commissione europea per facilitarne la comprensione. Leggi le condizioni d’uso.
Final Report Summary - TMAC (TARGETING TUMOUR ASSOCIATED MACROPHAGES IN CANCER)
These studies have established that IKKb/NF-kB signalling in tumour-associated myeloid cells contributes to immune suppression and promotes tumour growth, this suggests IKKb could be an important immune-checkpoint that can be targeted for immunotherapy in cancer. Based on these studies efforts are ongoing to develop strategies to target IKKb inhibitors specifically to myeloid cells in tumours as a novel immune-checkpoint therapy, we hope hope these further studies will lead to new therapeutic approaches for cancer.